Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

AACR 2024 | The advantages of cryo-immune vaccinations in treating metastatic cancers

George Prendergast • 8 Apr 2024
AACR 2024
General

George Prendergast, PhD, Lankenau Institute for Medical Research (LIMR), Wynnewood, PA, comments on the benefits of cryo-immune vaccinations over conventional immunotherapy. Combination therapies consisting of multiple immunotherapies, such as anti-CTLA-4 with anti-PD-L1 blockade, can be very toxic, and cryo-immune vaccinations enables locoregional treatment, where tumor cells will release antigens upon cryolysis. This interview took place at American Association for Cancer Research (AACR) Annual Meeting 2024 in San Diego, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from George Prendergast

0:45
SYNC-T combination immunotherapy in mCRPC
George Prendergast • 8 Apr 2024
2:33
Preclinical modelling of cryo-immune vaccination in solid tumors
George Prendergast • 8 Apr 2024

Related Videos

2:03
Biomarker detection for early cancer detection
Robert Rintoul • 19 Apr 2024
0:29
Innovative ctDNA-based liquid biopsy techniques for cancer diagnosis
Alain Thierry • 9 Apr 2024
0:50
Employing fragmentomics as a novel strategy to characterize and detect cancers
Alain Thierry • 9 Apr 2024
1:27
Emerging trials in melanoma: SWOG S1801, OpACIN-neo and PRADO
Christoffer Gebhardt • 9 Apr 2024
The content of VJOncology is intended for healthcare professionals